Copyright
©The Author(s) 2016.
World J Clin Oncol. Aug 10, 2016; 7(4): 331-336
Published online Aug 10, 2016. doi: 10.5306/wjco.v7.i4.331
Published online Aug 10, 2016. doi: 10.5306/wjco.v7.i4.331
Ref. | Regimen | Study design | Number of patients | Disease stage | Toxicity | Clinical efficacy |
Moreno-Aspitia et al[14] | Sorafenib as monotherapy | Phase II; 1 arm | 23 | Stage IV | Manageable | Low |
Bianchi et al[15] | Sorafenib as monotherapy | Phase II; 1 arm | 54 | Stage IV | Manageable | Low |
Gradishar et al[16] | Sorafenib + paclitaxel | RCT (vs placebo) | 237 | Stage IV | Manageable | Better TTP |
NCT00622466 (ongoing)[17] | Sorafenib + paclitaxel | RCT (vs placebo) | 41 | Stage IV | NA | NA |
NCT00499525 (ongoing)[17] | Sorafenib + paclitaxel | RCT (vs placebo) | 180 | Stages III-IV | NA | NA |
Mariani et al[18] | Sorafenib + docetaxel and/or letrozole | RCT (vs placebo) | 218 | Stage IV | Manageable | Not better |
Baselga et al[19] | Sorafenib + capecitabine | RCT (vs placebo) | 229 | Stage IV | High | Better PFS |
Baselga et al[20] (ongoing) | Sorafenib + capecitabine | RCT (vs placebo) | 519 | Stage IV | NA | NA |
Schwartzberg et al[21] | Sorafenib + gemcitabine and/or capecitabine | RCT (vs placebo) | 160 | Stages III-IV | Manageable | Better PFS |
Luu et al[22] | Sorafenib + vinorelbine | Phase I/II; 1 arm | 11/35 | Stage IV | Manageable | Low |
Mina et al[23] | Sorafenib + bevacizumab | Phase II; 1 arm | 18 | Stage IV | Substantial | Low |
NCT02624700 (ongoing)[17] | Sorafenib + pemetrexed | Phase II; 1 arm | 35 | Stage IV | NA | NA |
Yardley et al[24] | Sorafenib + ixabepilone | Phase I/II; 1 arm | 10/76 | Stage IV | High | Low |
Isaacs et al[25] | Sorafenib + anastrozole | Phase I/II; 1 arm | 35 | Stage IV | High | Benefit 23% |
Massarweh et al[26] | Sorafenib + endocrine therapy1 | Phase II; 1 arm | 11 | Stage IV | Manageable | Promising4 |
NCT00634634 (ongoing)[17] | Sorafenib + letrozole | Phase I/II; 1 arm | 54 | Stage IV | NA | NA |
NCT01724606 (ongoing)[17] | Sorafenib + WBRT | Phase I | 24 | Stage IV | NA | NA |
NCT01621906 (ongoing)[17] | Sorafenib + WBRT (18F-FLT-PET vs MRI) | Diagnostic | 20 | Stage IV | NA | NA |
Spigel et al[27] | Sorafenib + AC-T2 | One arm | 45 | Stages I-III | Limited | NA |
Loibl et al[28] | Sorafenib + EC-T3 | Phase II | 36 | Stages II-III | Manageable | pCR 27.7% |
Bazzola et al[29] | Sorafenib + letrozole + cyclophosphamide3 | One arm | 13 | Stages II-III | Tolerable | Clinical /no pCR |
- Citation: Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol 2016; 7(4): 331-336
- URL: https://www.wjgnet.com/2218-4333/full/v7/i4/331.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i4.331